NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
Key Highlights
- ➤C$80.1 million cash expected to fund operations through RESTORE topline readout in 1H 2028
- ➤RESTORE Phase 3 enrollment ongoing; completion expected in 2H 2027
- ➤FDA granted NVG-291 Breakthrough Therapy designation for chronic cervical motor-incomplete SCI
- ➤NervGen plans multidisciplinary Type B FDA meeting to discuss expediting NVG-291 development
- ➤Q3 R&D expenses rose to C$7.9 million; net loss reached C$6.4 million
Expert Statements
Adam Rogers, MD, President and Chief Executive Officer of NervGen
“Today, NervGen is actively enrolling participants in RESTORE under an FDA-aligned Phase 3 registrational design, and NVG-291 has received FDA Breakthrough Therapy designation, reinforcing its therapeutic potential, supported by promising preliminary clinical evidence from CONNECT SCI.”
Adam Rogers, MD, President and Chief Executive Officer of NervGen
“During the third quarter, we were honored to join the SCI community as an industry sponsor of the first-ever externally led SCI Patient-Focused Drug Development meeting, held during SCI Awareness Month to help ensure community perspectives inform ongoing and future treatment development.”
Adam Rogers, MD, President and Chief Executive Officer of NervGen
“Additionally, at our inaugural R&D Day, we highlighted the scientific and clinical foundation for NVG-291 and its potential as a pipeline-in-a-product.”
Adam Rogers, MD, President and Chief Executive Officer of NervGen
“As NervGen continues to grow and RESTORE enrollment advances, we remain steadfast in our commitment to rigorous oversight, working closely with investigators and site staff to maintain high standards of study execution.”
* Company plans to request a multidisciplinary Type B meeting with FDA to discuss NVG-291’s continued development and opportunities to expedite the program following Breakthrough Therapy designation * Enrollment ongoing in the Phase 3 RESTORE study, with continued activation of additional clinical sites, including designated SCI Model Systems centers * Phase 1b/2a CONNECT SCI manuscript in final preparation for submission to a peer-reviewed journal * Well-funded with C$80.1 million (US$56.5 million) in cash as of September 30, 2026, expected to fund operations through anticipated RESTORE topline readout in 1H 2028 MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today reported financial results for the third quarter ended September 30, 2026, and provided business updates.
Get started
Create a free account to read the full story.
